**Pharmacokinetic Evaluation of a One-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia**

# **Supplemental Digital Content 2**

Cytochrome P450 2D6 polymorphisms were evaluated using Sanger sequencing, TaqMan chemistry, or gel-based genotyping methods. Patients were classified as extensive, intermediate, or poor metabolizers based on haplotype of the genotyped variants. Patients were classified as poor metabolizers if they possessed two non-functioning alleles, intermediate metabolizers if they had one non-functioning allele and one normal-functioning allele, or extensive metabolizers for any other combination (**Supplemental Table S1**). If the genotype for a single nucleotide polymorphism could not be determined or was missing, then the metabolizer status was unknown unless it could be extrapolated from the known genotypes.

## SUPPLEMENTAL TABLE S1. CYP2D6 alleles tested, the associated enzyme activity, and gene result/phenotype association

|  |  |  |
| --- | --- | --- |
| **CYP2D6 allele** | **Enzyme activity** | **Priority\*** |
| \*3 | No activity | 1 |
| \*4 | No activity | 2 |
| \*5 | No activity | 3 |
| \*6 | No activity | 4 |
| \*7 | No activity | 5 |
| \*8 | No activity | 6 |
| \*11 | No activity | 7 |
| \*15 | No activity | 8 |
| \*16 | No activity | 9 |
| \*21 | No activity | 10 |
| \*9 | Reduced activity | 11 |
| \*17 | Reduced activity | 12 |
| \*19 | Reduced activity | 13 |
| \*20 | Reduced activity | 14 |
| \*29 | Reduced activity | 15 |
| \*35 | Reduced activity | 16 |
| \*36 | Reduced activity | 17 |
| \*40 | Reduced activity | 18 |
| \*41 | Reduced activity | 19 |
| \*10 | Reduced activity | 20 |
| Gene duplication | Ultra-rapid activity | 21 |
| \*2 | Normal activity | 22 |
| \*1 (wt) | Normal activity | 23 |
| **Gene result/phenotype association** |
| **Gene result combination** | **Predicted phenotype** |
| Ultra-rapid activity/normal activity | Ultra-rapid metabolizer |
| Ultra-rapid activity/reduced activity | Extensive metabolizer |
| Ultra-rapid activity/no activity | Extensive metabolizer |
| Normal activity/normal activity | Extensive metabolizer |
| Normal activity/reduced activity | Extensive metabolizer |
| Normal activity/no activity | Intermediate metabolizer |
| Reduced activity/reduced activity | Intermediate metabolizer |
| Reduced activity/no activity | Intermediate metabolizer |
| No activity/no activity | Poor metabolizer |

\*How the individual alleles for the CYP2D6 gene are prioritized in determining the final genotype and phenotype.

wt, wild type.